Landfar Bio-medicine Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Landfar Bio-medicine's earnings have been declining at an average annual rate of -50.7%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been declining at an average rate of 0.03% per year.
Belangrijke informatie
-50.7%
Groei van de winst
-50.7%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 11.3% |
Inkomstengroei | -0.03% |
Rendement op eigen vermogen | -20.0% |
Nettomarge | -29.8% |
Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
There's Reason For Concern Over Landfar Bio-medicine Co., Ltd's (SZSE:000504) Massive 37% Price Jump
Oct 21Risks Still Elevated At These Prices As Landfar Bio-medicine Co., Ltd (SZSE:000504) Shares Dive 31%
Jun 09Landfar Bio-medicine Co., Ltd's (SZSE:000504) Popularity With Investors Under Threat As Stock Sinks 32%
Apr 17Landfar Bio-medicine Co., Ltd (SZSE:000504) Investors Are Less Pessimistic Than Expected
Mar 01Opbrengsten en kosten
Hoe Landfar Bio-medicine geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Sep 24 | 124 | -37 | 107 | 13 |
30 Jun 24 | 123 | -28 | 113 | 12 |
31 Mar 24 | 128 | -29 | 113 | 13 |
31 Dec 23 | 137 | -28 | 116 | 13 |
30 Sep 23 | 149 | -13 | 129 | 10 |
30 Jun 23 | 161 | -24 | 131 | 10 |
31 Mar 23 | 170 | -15 | 131 | 10 |
31 Dec 22 | 200 | -12 | 137 | 10 |
30 Sep 22 | 210 | -10 | 121 | 9 |
30 Jun 22 | 199 | -11 | 121 | 9 |
31 Mar 22 | 188 | -20 | 127 | 9 |
01 Jan 22 | 157 | -19 | 122 | 9 |
30 Sep 21 | 174 | 3 | 98 | 8 |
30 Jun 21 | 201 | 4 | 89 | 6 |
31 Mar 21 | 190 | 11 | 77 | 5 |
31 Dec 20 | 176 | 8 | 69 | 5 |
30 Sep 20 | 149 | 35 | 58 | 12 |
30 Jun 20 | 116 | 31 | 64 | 12 |
31 Mar 20 | 123 | 24 | 71 | 13 |
31 Dec 19 | 134 | 19 | 76 | 16 |
30 Sep 19 | 130 | -32 | 80 | 18 |
30 Jun 19 | 120 | -34 | 73 | 19 |
31 Mar 19 | 108 | -34 | 68 | 18 |
31 Dec 18 | 95 | -35 | 60 | 16 |
30 Sep 18 | 106 | -40 | 66 | 7 |
30 Jun 18 | 89 | -41 | 57 | 6 |
31 Mar 18 | 82 | -39 | 47 | 4 |
31 Dec 17 | 67 | -37 | 41 | 3 |
30 Sep 17 | 72 | 17 | 31 | 2 |
30 Jun 17 | 76 | 22 | 29 | 0 |
31 Mar 17 | 69 | 22 | 29 | 0 |
31 Dec 16 | 67 | 22 | 28 | 0 |
30 Sep 16 | 16 | -27 | 27 | 0 |
30 Jun 16 | 13 | -26 | 25 | 0 |
31 Mar 16 | 14 | -22 | 22 | 0 |
31 Dec 15 | 13 | -21 | 21 | 0 |
30 Sep 15 | 15 | -23 | 22 | 0 |
30 Jun 15 | 15 | -24 | 21 | 0 |
31 Mar 15 | 16 | -25 | 23 | 0 |
31 Dec 14 | 18 | -26 | 25 | 0 |
30 Sep 14 | 23 | 16 | 23 | 0 |
30 Jun 14 | 25 | 18 | 24 | 0 |
31 Mar 14 | 27 | 17 | 22 | 0 |
31 Dec 13 | 26 | 14 | 22 | 0 |
Kwaliteitswinsten: 000504 is currently unprofitable.
Groeiende winstmarge: 000504 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 000504 is unprofitable, and losses have increased over the past 5 years at a rate of 50.7% per year.
Versnelling van de groei: Unable to compare 000504's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: 000504 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.08%).
Rendement op eigen vermogen
Hoge ROE: 000504 has a negative Return on Equity (-20.04%), as it is currently unprofitable.